Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative Sénégalaise d'Accès Aux Antirétroviraux (ISAARV) Program

Trial Profile

Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative Sénégalaise d'Accès Aux Antirétroviraux (ISAARV) Program

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darunavir/ritonavir (Primary) ; Emtricitabine (Primary) ; Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Raltegravir (Primary) ; Tenofovir dipivoxil fumarate (Primary) ; Zidovudine (Primary)
  • Indications HIV-2 infections
  • Focus Therapeutic Use
  • Acronyms RESIST-2
  • Most Recent Events

    • 16 Aug 2019 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
    • 16 Aug 2019 Planned primary completion date changed from 1 Jan 2021 to 1 Jan 2022.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top